A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Neuroendocrine Tumors Clinical Trial

— GI-NETorPNET  

Official title:

A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02132468
• Other study ID #: OX4218s
• Status: Completed
• Phase: Phase 2
• First received: May 2, 2014
• Last updated: October 31, 2017
• Start date: September 2014
• Est. completion date: August 2016

Study information

• Verified date: October 2017
• Source: Mateon Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or Gastrointestinal Neuroendocrine tumors (GI-NETs) with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies, including octreotide, chemotherapy or targeted therapy.

Description:

Subjects enrolled in this PNET/GI-NET study (OX4218s) will receive weekly dosing with fosbretabulin for up to 3 cycles or approximately 9 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: August 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to read, understand and provide written consent to participate in the study

• Age = 18 years

• Biopsy-proven well-differentiated, low-to-intermediate-grade PNET or GI-NET with elevated (> ULN) biomarkers (serotonin, 5-hydroxyindoleacetic acid (5-HIAA), chromogranin A (CgA), neurokinin A, and neuron-specific enolase (NSE))

• Life expectancy > 12 weeks

• Must have received or may still be receiving one or more therapies including octreotide or serotonin synthesis inhibitor (SSI) or other somatostatin analogues

• Confirmed progressive disease within 18 months of enrollment on study

• Recovered from prior radiation therapy or surgery

• Eastern Cooperative Oncology Group (ECOG) performance score 0-2

• Absolute neutrophil count (ANC) = 1,500/µL (without growth factors)

• Platelet count = 100,000/µL

• Adequate renal function as evidenced by serum creatinine

= 2.0 mg/dL (177 µmol/L)

• Adequate hepatic function: serum total bilirubin = 2X greater than the upper limit of normal (ULN) (= 3X ULN in subjects with liver metastases), aspartate aminotransferase) AST) / alanine aminotransferase (AST) = 2X the ULN for the local reference lab (= 5X the ULN for subjects with liver metastases)

• Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide imaging or other imaging modality)

• Women of childbearing potential as well as fertile men and their partners must use an effective method of birth control

Exclusion Criteria:

• Inadequately controlled hypertension defined as BP > 150/100 mm Hg despite medication

• Prior history of hypertensive crisis or hypertensive encephalopathy

• Recent history (within 6 months of start of screening) of unstable angina pectoris pattern, myocardial infarction (including non-Q wave MI), or NYHA (New York Heart Association) Class III and IV Congestive Heart Failure (CHF)

• Subjects who have clinical evidence of carcinoid-induced heart disease

• History of prior cerebrovascular accident (CVA), including transient ischemic attach (TIA)

• Known central nervous system (CNS) disease except for treated brain metastasis

• History of torsade de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (<60 bpm), heart block (excluding 1st degree block, being PR interval prolongation only), congenital long QT syndrome or new ST segment elevation or depression or new Q wave on ECG

• Corrected QT interval (QTc) > 480 msec

• Ongoing treatment with any drugs known to prolong the QTc interval, including anti-arrhythmic medications (stable regimen of antidepressants of the selective serotonin reuptake inhibitor (SSRI) class is allowed))

• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

• Significant vascular disease or recent peripheral arterial thrombosis

• Known intolerance of or hypersensitivity to fosbretabulin

• History of solid organ transplant or bone marrow transplant

• Any other intercurrent medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results

• High grade or poorly differentiated NET

• NET tumor other than PNET or GI-NET

• No elevated biomarker (>ULN) that can be followed

• Received regional hepatic infusion therapy within 6 months of enrollment (RFA allowed >6 months prior to enrollment)

Related Conditions & MeSH terms

• Carcinoid Tumor
• Neuroendocrine Tumors

Intervention

Drug:
• fosbretabulin tromethamine
60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity

Locations

Country	Name	City	State
United States	Montefiore	Bronx	New York
United States	Duke University Medical Center	Durham	North Carolina
United States	Markey Cancer Center, Clinical Research Office	Lexington	Kentucky
United States	Froedtert Hospital, Medicial College of Wisconsin	Milwaukee	Wisconsin
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Mateon Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline	The mean change from baseline in chromogranin A (CgA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%.	Baseline and 4 months
Primary	Number of Participants With Improved, Stable, or Worsened Change In 5-hydroxyindoleacetic Acid (5-HIAA) Biomarker Levels From Baseline	The mean change from baseline in 5-hydroxyindoleacetic acid (5-HIAA) biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%.	Baseline and 4 months
Primary	Number of Participants With Improved, Stable, or Worsened Change In Serotonin Biomarker Levels From Baseline	The mean change from baseline in serotonin biomarker level is considered improved if a 25% reduction occurs and worsened if the mean change from baseline is increased by 25%.	Baseline and 4 months
Secondary	Number of Participants With Partial Response (PR), Progressive Disease (PD), or Stable Disease (SD) Based on RECIST 1.1	The objective response rate (complete response, partial response, progressive disease, or stable disease) was determined by the investigator assessment of the participant's CT or MRI using Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) for target lesions. Partial Response (PR) is when there is at least 30% decrease in sum of the longest diameter of the target lesions. Progressive Disease (PD) is when there is at least 20% increase in the sum of the longest diameter of the target lesions, as well as an absolute increase of at least 5 mm (including appearance of new lesions). Stable Disease (SD) is when there neither a PR nor PD is noted.	Baseline and 4 months